The Medicines Co. evaluates clevidipine in phase 3 trials

By Lisa Kerner

Charlotte, N.C., Sept. 11 - The Medicines Co. completed patient enrollment and follow-up of its Eclipse series of safety evaluations of clevidipine calcium channel blocker in the perioperative treatment of hypertension.

The company also began its multi-center, single-arm, open-label phase 3 Velocity trial in 100 patients presenting severely elevated blood pressure in the emergency department or intensive-care unit.

Velocity said it will evaluate the safety of a titration dosing regimen of an intravenous infusion of clevidipine given continuously for at least 18 hours.

The Medicines Co. plans to submit an application for clevidipine U.S. marketing approval in the first half of 2007.

Based in Parsippany, N.J., The Medicines Co. develops products for acute hospital care.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.